Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Nasopharyngeal Carcinoma 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Radiation Pneumonitis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Non Squamous Non-small Cell Lung Cancer 1Neoplasms 1Neoplasm Recurrence, Local 1Motor Activity 1Gastric Cancer Stage 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1B-cell Malignancies 1Advanced Squamous Non-Small Cell Lung Carcinoma 1Advanced Squamous Non Small Cell Lung Cancer 1Advanced Non-squamous Non-small-cell Lung Cancer 1

Interventions

Gemcitabine 12Mitomycin 11Cisplatin 10Carboplatin 8pembrolizumab 7Docetaxel 4toripalimab 3avelumab 3atezolizumab 3Paclitaxel 3sacituzumab govitecan 2disitamab vedotin 2Taxes 2Specimen Handling 2Platinum 2Magnetic Resonance Spectroscopy 2Injections 21,2-diaminocyclohexaneplatinum II citrate 2vinflunine 1valrubicin 1tislelizumab 1lenvatinib 1eribulin 1epacadostat 1enfortumab vedotin 1durvalumab 1dodecyl maltoside 1Vitamin B 12 1Standard of Care 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Transitional Cell × tislelizumab × Clear all
NCT03967977 2026-04-23

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

BeOne Medicines

Phase 3 Active not recruiting
420 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡